Niagen Bioscience, Inc. Common Stock NAGE Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Sales by Business | ||||||
| Analytical Reference Standards and Services segment | $423K-47.8% | —— | $772K-1.5% | $799K+1.0% | $811K+13.6% | |
| Consumer Products segment | $22.41M+4.2% | —— | $26.02M+43.6% | $22.7M+21.7% | $21.5M+23.9% | |
| Corporate and other | $74K— | —— | —— | —— | —— | |
| Ingredients segment | $8.56M+4.8% | —— | $7.2M+7.9% | $7.62M+131% | $8.17M+99.8% | |
| Pharmaceuticals segment | $0— | —— | —— | —— | $0— | |
| Gross Profit by Business | ||||||
| Analytical Reference Standards and Services segment | $115K-32.0% | —— | $218K+65.2% | $169K+125% | $169K+2,013% | |
| Consumer Products segment | $14.82M+5.1% | —— | $17.46M+50.3% | $15.25M+28.5% | $14.09M+25.9% | |
| Ingredients segment | $5.01M-1.2% | —— | $4.25M-5.4% | $4.81M+174% | $5.07M+125% | |
| Pharmaceuticals segment | $0— | —— | —— | —— | $0— | |
| Operating Income (Loss) by Business | ||||||
| Analytical Reference Standards and Services segment | $71K+14.5% | —— | $138K+1,050% | $88K+273% | $62K+150% | |
| Consumer Products segment | $4.64M-15.8% | —— | $7.42M+95.8% | $6M+52.0% | $5.51M+89.7% | |
| Ingredients segment | $4.54M-4.4% | —— | $3.8M-7.3% | $4.36M+189% | $4.75M+158% | |
| Pharmaceuticals segment | -$468K-27.2% | —— | —— | —— | -$368K+16.3% | |
| Selling by Business | ||||||
| Analytical Reference Standards and Services segment | $44K-58.9% | $80K-35.0% | $79K-34.2% | $81K-34.1% | $107K-18.3% | |
| Consumer Products segment | $2.73M+8.8% | $2.79M+5.4% | $2.79M+23.1% | $2.68M+24.0% | $2.51M+13.3% | |
| Ingredients segment | $94K+91.8% | $50K+51.5% | $38K+522% | $7K-56.3% | $49K— | |
| Pharmaceuticals segment | $0— | —— | —— | —— | $0— | |
| Operating Expenses by Business | ||||||
| Analytical Reference Standards and Services segment | $44K-58.9% | —— | $80K-33.3% | $81K-35.7% | $107K-18.9% | |
| Consumer Products segment | $10.17M+18.6% | —— | $10.03M+28.3% | $9.24M+16.8% | $8.58M+3.5% | |
| Ingredients segment | $470K+47.3% | —— | $450K+13.9% | $450K+82.2% | $319K-22.6% | |
| Pharmaceuticals segment | $468K+27.2% | —— | —— | —— | $368K-16.3% | |
| Cost of Sales by Business | ||||||
| Analytical Reference Standards and Services segment | $308K-52.0% | —— | $554K-15.0% | $630K-12.0% | $642K-9.1% | |
| Consumer Products segment | $7.6M+2.5% | —— | $8.56M+31.4% | $7.45M+9.8% | $7.41M+20.4% | |
| Ingredients segment | $3.56M+14.6% | —— | $2.94M+35.3% | $2.81M+81.7% | $3.1M+68.8% | |
| Pharmaceuticals segment | $0— | —— | —— | —— | $0— | |
| Marketing by Business | ||||||
| Analytical Reference Standards and Services segment | $0— | $1K— | $1K— | $0-100% | $0-100% | |
| Consumer Products segment | $3.42M+39.5% | $3.82M+55.4% | $2.7M+40.6% | $2.51M+21.5% | $2.45M+29.3% | |
| Ingredients segment | $96K+284% | $15K-87.3% | $17K+13.3% | $45K-10.0% | $25K+108% | |
| Pharmaceuticals segment | $0— | —— | —— | —— | $0— | |
| R&D by Business | ||||||
| Analytical Reference Standards and Services segment | $0— | —— | $0— | $0— | $0— | |
| Consumer Products segment | $733K+13.6% | —— | $1.4M+55.4% | $1.17M+3.0% | $645K-61.9% | |
| Ingredients segment | $280K+14.3% | —— | $395K+1.5% | $398K+120% | $245K-38.8% | |
| Pharmaceuticals segment | $468K+27.2% | —— | —— | —— | $368K-16.3% | |
| G&A by Business | ||||||
| Analytical Reference Standards and Services segment | $0— | —— | $0— | $0— | $0— | |
| Consumer Products segment | $0— | —— | $0— | $0— | $0— | |
| Ingredients segment | $0— | —— | $0— | $0— | $0— | |
| Pharmaceuticals segment | $0— | —— | —— | —— | $0— | |
| Advertising by Business | ||||||
| Analytical Reference Standards and Services segment | $0— | $0— | $0— | $0— | $0— | |
| Consumer Products segment | $3.29M+10.6% | $3.65M+9.6% | $3.15M+15.0% | $2.88M+13.1% | $2.98M+19.7% | |
| Ingredients segment | $0— | $0— | $0— | $0— | $0— | |
| Pharmaceuticals segment | $0— | —— | —— | —— | $0— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Niagen Bioscience, Inc. Common Stock break its business down?
- Niagen Bioscience, Inc. Common Stock (NAGE) reports net sales by business across 5 parts — Analytical Reference Standards and Services segment, Consumer Products segment, Corporate and other, Ingredients segment and Pharmaceuticals segment. Each is extracted from the segment footnotes and tracked over time.
- Where does Niagen Bioscience, Inc. Common Stock's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Niagen Bioscience, Inc. Common Stock's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
